Display options
Cite
Höflmayer D, Fraune C, Hube-Magg C, et al. Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Appl Immunohistochem Mol Morphol. 2021;29(4):e29-e38doi: 10.1097/PAI.0000000000000901.
Höflmayer, D., Fraune, C., Hube-Magg, C., Simon, R., Schroeder, C., Büscheck, F., Möller, K., Dum, D., Weidemann, S., Wittmer, C., Schlomm, T., Huland, H., Heinzer, H., Graefen, M., Haese, A., Sauter, G., Burandt, E., Clauditz, T. S., Steurer, S., Minner, S., Wilczak, W., & Polonski, A. (2021). Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Applied immunohistochemistry & molecular morphology : AIMM, 29(4), e29-e38. https://doi.org/10.1097/PAI.0000000000000901
Höflmayer, Doris, et al. "Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer." Applied immunohistochemistry & molecular morphology : AIMM vol. 29,4 (2021): e29-e38. doi: https://doi.org/10.1097/PAI.0000000000000901
Höflmayer D, Fraune C, Hube-Magg C, Simon R, Schroeder C, Büscheck F, Möller K, Dum D, Weidemann S, Wittmer C, Schlomm T, Huland H, Heinzer H, Graefen M, Haese A, Sauter G, Burandt E, Clauditz TS, Steurer S, Minner S, Wilczak W, Polonski A. Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. Appl Immunohistochem Mol Morphol. 2021 Apr 01;29(4):e29-e38. doi: 10.1097/PAI.0000000000000901. PMID: 33491944.
Copy Download .nbib Format: NLM
Share it on

Appl Immunohistochem Mol Morphol. 2021 Apr 01;29(4):e29-e38. doi: 10.1097/PAI.0000000000000901.

Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer.

Applied immunohistochemistry & molecular morphology : AIMM

Doris Höflmayer, Christoph Fraune, Claudia Hube-Magg, Ronald Simon, Cornelia Schroeder, Franziska Büscheck, Katharina Möller, David Dum, Sören Weidemann, Corinna Wittmer, Thorsten Schlomm, Hartwig Huland, Hans Heinzer, Markus Graefen, Alexander Haese, Guido Sauter, Eike Burandt, Till S Clauditz, Stefan Steurer, Sarah Minner, Waldemar Wilczak, Adam Polonski

Affiliations

  1. Institute of Pathology.
  2. General, Visceral and Thoracic Surgery Department and Clinic.
  3. Department of Urology, Charité-Universitätsmedizin Berlin, Germany.
  4. Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg, Eppendorf.

PMID: 33491944 DOI: 10.1097/PAI.0000000000000901

Abstract

Tripartite motif containing 24 (TRIM24) is a multifunctional protein involved in p53 degradation, chromatin binding, and transcriptional modulation of nuclear receptors. Emerging research has revealed that upregulation of TRIM24 in numerous tumor types is linked to poor prognosis, attributing an important role to TRIM24 in tumor biology. In order to better understand the role of TRIM24 in prostate cancer, we analyzed its immunohistochemical expression on a tissue microarray containing >17,000 prostate cancer specimens. TRIM24 immunostaining was detectable in 61% of 15,321 interpretable cancers, including low expression in 46% and high expression in 15% of cases. TRIM24 upregulation was associated with high Gleason grade, advanced pathologic tumor stage, lymph node metastasis, higher preoperative prostate-specific antigen level, increased cell proliferation as well as increased genomic instability, and predicted prognosis independent of clinicopathologic parameters available at the time of the initial biopsy (all P<0.0001). TRIM24 upregulation provides additional prognostic information in prostate cancer, particularly in patients with low Gleason grade tumors who may be eligible for active surveillance strategies, suggesting promising potential for TRIM24 in the routine diagnostic work-up of these patients.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
  2. Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319:1914–1931. - PubMed
  3. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377:132–142. - PubMed
  4. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
  5. Ozato K, Shin DM, Chang TH, et al. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8:849–860. - PubMed
  6. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11:792–804. - PubMed
  7. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases. BioEssays. 2005;27:1147–1157. - PubMed
  8. Zhang J, Xu Z, Yu B, et al. Tripartite motif containing 35 contributes to the proliferation, migration, and invasion of lung cancer cells in vitro and in vivo. Biosci Rep. 2020;40:4. - PubMed
  9. Han Y, Tan Y, Zhao Y, et al. TRIM23 overexpression is a poor prognostic factor and contributes to carcinogenesis in colorectal cancer. J Cell Mol Med. 2020;24:5491–5500. - PubMed
  10. Jaworska AM, Wlodarczyk NA, Mackiewicz A, et al. The role of TRIM family proteins in the regulation of cancer stem cell self-renewal. Stem Cells. 2020;38:165–173. - PubMed
  11. Appikonda S, Thakkar KN, Shah PK, et al. Cross-talk between chromatin acetylation and SUMOylation of tripartite motif-containing protein 24 (TRIM24) impacts cell adhesion. J Biol Chem. 2018;293:7476–7485. - PubMed
  12. Le Douarin B, Zechel C, Garnier JM, et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 1995;14:2020–2033. - PubMed
  13. Le Douarin B, Nielsen AL, Garnier JM, et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996;15:6701–6715. - PubMed
  14. Allton K, Jain AK, Herz HM, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA. 2009;106:11612–11616. - PubMed
  15. Jain AK, Barton MC. Regulation of p53: TRIM24 enters the RING. Cell Cycle. 2009;8:3668–3674. - PubMed
  16. Bennett J, Fedorov O, Tallant C, et al. Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem. 2016;59:1642–1647. - PubMed
  17. Palmer WS, Poncet-Montange G, Liu G, et al. Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem. 2016;59:1440–1454. - PubMed
  18. Wang J, Zhu J, Dong M, et al. Knockdown of tripartite motif containing 24 by lentivirus suppresses cell growth and induces apoptosis in human colorectal cancer cells. Oncol Res. 2014;22:39–45. - PubMed
  19. Chambon M, Orsetti B, Berthe ML, et al. Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. Am J Pathol. 2011;178:1461–1469. - PubMed
  20. Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010;468:927–932. - PubMed
  21. Li H, Sun L, Tang Z, et al. Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One. 2012;7:e37657. - PubMed
  22. Xue D, Zhang X, Zhang X, et al. Clinical significance and biological roles of TRIM24 in human bladder carcinoma. Tumour Biol. 2015;36:6849–6855. - PubMed
  23. Miao ZF, Wang ZN, Zhao TT, et al. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance. Virchows Archiv. 2015;466:525–532. - PubMed
  24. Groner AC, Cato L, de Tribolet-Hardy J, et al. TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell. 2016;29:846–858. - PubMed
  25. Offermann A, Roth D, Hupe MC, et al. TRIM24 as an independent prognostic biomarker for prostate cancer. Urol Oncol. 2019;37:576 e1–576 e10. - PubMed
  26. Schlomm T, Iwers L, Kirstein P, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008;21:1371–1378. - PubMed
  27. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–847. - PubMed
  28. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23:159–170. - PubMed
  29. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2011;17:5878–5888. - PubMed
  30. Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73:2795–2805. - PubMed
  31. Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol. 2013;26:975–983. - PubMed
  32. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012;181:401–412. - PubMed
  33. Krohn A, Seidel A, Burkhardt L, et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol. 2013;231:130–141. - PubMed
  34. Epstein JI, Feng Z, Trock BJ, et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019–1024. - PubMed
  35. Cui Z, Cao W, Li J, et al. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One. 2013;8:e63887. - PubMed
  36. McCall P, Witton CJ, Grimsley S, et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer. 2008;99:1296–1301. - PubMed
  37. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol. 2009;218:505–513. - PubMed
  38. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–2190. - PubMed
  39. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131. - PubMed
  40. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–131. - PubMed
  41. Sauter G, Steurer S, Clauditz TS, et al. Clinical utility of quantitative Gleason Grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69:592–598. - PubMed
  42. Jain AK, Allton K, Duncan AD, et al. TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol. 2014;34:2695–2709. - PubMed
  43. Liu X, Huang Y, Yang D, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One. 2014;9:e85462. - PubMed
  44. Appikonda S, Thakkar KN, Barton MC. Regulation of gene expression in human cancers by TRIM24. Drug Discov Today Technol. 2016;19:57–63. - PubMed
  45. Kikuchi M, Okumura F, Tsukiyama T, et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. 2009;1793:1828–1836. - PubMed
  46. vom Baur E, Zechel C, Heery D, et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 1996;15:110–124. - PubMed
  47. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648. - PubMed
  48. Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011;11:507. - PubMed
  49. Kim JH, Dhanasekaran SM, Mehra R, et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 2007;67:8229–8239. - PubMed
  50. Sun J, Liu W, Adams TS, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007;67:692–700. - PubMed
  51. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. - PubMed
  52. Baliou E, Nonni A, Keramopoulos D, et al. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma. J BUON. 2016;21:1099–1103. - PubMed
  53. Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005;5:27–41. - PubMed
  54. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453–3459. - PubMed
  55. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420:25–27. - PubMed
  56. Carroll PE, Okuda M, Horn HF, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene. 1999;18:1935–1944. - PubMed
  57. Ravindranathan P, Lee TK, Yang L, et al. Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nat Commun. 2013;4:1923. - PubMed
  58. Skaar JR, Pagan JK, Pagano M. SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov. 2014;13:889–903. - PubMed
  59. Sauter G. Representativity of TMA studies. Methods Mol Biol. 2010;664:27–35. - PubMed

Publication Types